Share Price and Basic Stock Data
Last Updated: October 27, 2025, 9:10 pm
| PEG Ratio | 0.24 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Cravatex Ltd operates in the trading and distribution sector, with a current market price of ₹420 and a market capitalization of ₹108 Cr. The company reported a sales figure of ₹504 Cr for the fiscal year ending March 2023, which marked a decline from the previous year’s ₹594 Cr. The quarterly sales figures indicate a downward trend, with the most recent quarter (June 2024) recording only ₹25.78 Cr, down from ₹162.40 Cr in June 2022. This decline is concerning, highlighting challenges in maintaining revenue streams amid fluctuating market conditions. The operating profit margin (OPM) stood at a negative 26.42%, indicating ongoing operational inefficiencies. The company’s ability to convert sales into profit has been hampered, as seen in the reported operating loss across multiple quarters. Overall, the revenue trend reflects potential underlying issues in demand or operational execution, necessitating a closer examination of market strategies.
Profitability and Efficiency Metrics
Cravatex Ltd’s profitability metrics reflect significant volatility, evidenced by its fluctuating net profit figures. The company reported a net profit of ₹59 Cr in FY 2023, a stark contrast to the losses recorded in previous years. However, the trailing twelve months (TTM) net profit stood at ₹3 Cr, showcasing the difficulty in maintaining profitability consistency. The return on equity (ROE) is relatively low at 4.68%, while the return on capital employed (ROCE) is marginally better at 6.57%. Efficiency metrics such as the cash conversion cycle (CCC) currently at 47 days indicate some improvement in working capital management compared to the previous fiscal year. However, the interest coverage ratio of 20.39x suggests that the company can comfortably meet its interest obligations, indicating a cushion against financial distress. Despite these positive indicators, the negative operating profit margin raises concerns about cost management and operational effectiveness.
Balance Sheet Strength and Financial Ratios
Cravatex Ltd demonstrates a solid balance sheet position with no outstanding borrowings, reflecting a debt-free status that is advantageous in terms of financial flexibility. The reserves have grown to ₹104 Cr, demonstrating a positive trend in retained earnings. The company’s liquidity ratios are quite robust, with a current ratio of 4.22 and a quick ratio of 3.86, indicating strong short-term financial health. The price-to-book value ratio (P/BV) stands at 0.83x, suggesting that the stock may be undervalued relative to its book value, which could attract potential investors. However, the operating profit margin remains a concern, and the company’s ability to convert its assets into revenues effectively is questionable, as indicated by the declining revenue from operations per share, which stood at ₹672.41 for FY 2025. These financial ratios, while indicating strength, also highlight the need for improved operational efficiency to leverage the strong balance sheet.
Shareholding Pattern and Investor Confidence
Cravatex Ltd’s shareholding structure shows a strong promoter backing, with promoters holding 75% of the shares, providing stability and confidence in management’s strategic direction. The public segment holds the remaining 25%, with the number of shareholders increasing from 1,697 in September 2022 to 2,433 by June 2025. This increase indicates growing interest among retail investors, which could be a positive sign of market confidence. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raises questions regarding institutional confidence in the company’s growth prospects. The consistent promoter shareholding suggests alignment with long-term value creation; however, the lack of institutional participation could limit liquidity and broader market appeal. Overall, while the shareholding pattern reflects stability, the absence of institutional support may pose challenges for future capital raising.
Outlook, Risks, and Final Insight
If margins sustain improvement and operational efficiencies are realized, Cravatex Ltd could capitalize on its strong balance sheet and promoter support to enhance profitability. However, significant risks remain, including ongoing revenue volatility and operational inefficiencies that could hinder growth. The company’s ability to adapt to market demands and manage costs effectively will be crucial in navigating the current challenges. Furthermore, the lack of institutional interest could pose liquidity constraints, affecting the stock’s performance. Investors should watch key performance indicators closely, particularly sales trends and profitability metrics, to gauge the effectiveness of management strategies. Overall, while there are strengths in the balance sheet and promoter backing, addressing operational challenges will be critical for Cravatex Ltd to achieve sustainable growth in the competitive trading and distribution sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Cravatex Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Minal Industries Ltd | 69.3 Cr. | 3.61 | 5.59/3.20 | 41.2 | 2.77 | 0.00 % | 5.97 % | 2.83 % | 2.00 |
| Mitshi India Ltd | 13.4 Cr. | 15.2 | 18.6/13.0 | 446 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 |
| Modella Woollens Ltd | 5.99 Cr. | 65.8 | 74.2/52.5 | 3.63 | 0.00 % | % | % | 10.0 | |
| MRC Agrotech Ltd | 93.5 Cr. | 45.6 | 45.6/10.2 | 92.5 | 15.0 | 0.00 % | 5.89 % | 4.46 % | 10.0 |
| MRP Agro Ltd | 111 Cr. | 99.6 | 174/84.4 | 14.9 | 29.3 | 0.00 % | 39.2 % | 30.3 % | 10.0 |
| Industry Average | 10,916.62 Cr | 171.94 | 106.79 | 113.39 | 0.25% | 15.73% | 9.23% | 7.74 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 162.40 | 170.42 | 87.10 | 83.74 | 56.60 | 57.45 | 37.90 | 50.68 | 25.78 | 55.04 | 32.43 | 60.52 | 23.13 |
| Expenses | 166.43 | 176.91 | 103.63 | 87.03 | 56.42 | 59.62 | 41.69 | 52.56 | 28.11 | 53.03 | 34.30 | 60.01 | 29.24 |
| Operating Profit | -4.03 | -6.49 | -16.53 | -3.29 | 0.18 | -2.17 | -3.79 | -1.88 | -2.33 | 2.01 | -1.87 | 0.51 | -6.11 |
| OPM % | -2.48% | -3.81% | -18.98% | -3.93% | 0.32% | -3.78% | -10.00% | -3.71% | -9.04% | 3.65% | -5.77% | 0.84% | -26.42% |
| Other Income | 1.50 | 2.52 | 107.57 | 6.59 | 1.58 | 6.03 | 5.82 | 2.68 | 3.48 | 2.14 | 2.24 | 2.09 | 5.21 |
| Interest | 3.69 | 4.86 | 3.51 | 1.31 | 0.08 | 0.08 | 0.13 | 0.11 | 0.11 | 0.11 | 0.11 | 0.09 | 0.09 |
| Depreciation | 3.94 | 8.85 | 2.91 | 0.44 | 0.47 | 0.53 | 0.49 | 0.39 | 0.34 | 0.34 | 0.40 | 0.40 | 0.38 |
| Profit before tax | -10.16 | -17.68 | 84.62 | 1.55 | 1.21 | 3.25 | 1.41 | 0.30 | 0.70 | 3.70 | -0.14 | 2.11 | -1.37 |
| Tax % | 9.25% | 8.54% | -0.90% | -147.74% | 64.46% | 4.00% | 43.97% | -70.00% | 30.00% | 28.38% | -278.57% | 31.75% | 0.73% |
| Net Profit | -11.11 | -19.18 | 85.38 | 3.84 | 0.42 | 3.11 | 0.79 | 0.50 | 0.48 | 2.65 | 0.25 | 1.44 | -1.37 |
| EPS in Rs | -42.99 | -74.22 | 330.39 | 14.86 | 1.63 | 12.03 | 3.06 | 1.93 | 1.86 | 10.25 | 0.97 | 5.57 | -5.30 |
Last Updated: August 19, 2025, 8:35 pm
Below is a detailed analysis of the quarterly data for Cravatex Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.13 Cr.. The value appears to be declining and may need further review. It has decreased from 60.52 Cr. (Mar 2025) to 23.13 Cr., marking a decrease of 37.39 Cr..
- For Expenses, as of Jun 2025, the value is 29.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 60.01 Cr. (Mar 2025) to 29.24 Cr., marking a decrease of 30.77 Cr..
- For Operating Profit, as of Jun 2025, the value is -6.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.51 Cr. (Mar 2025) to -6.11 Cr., marking a decrease of 6.62 Cr..
- For OPM %, as of Jun 2025, the value is -26.42%. The value appears to be declining and may need further review. It has decreased from 0.84% (Mar 2025) to -26.42%, marking a decrease of 27.26%.
- For Other Income, as of Jun 2025, the value is 5.21 Cr.. The value appears strong and on an upward trend. It has increased from 2.09 Cr. (Mar 2025) to 5.21 Cr., marking an increase of 3.12 Cr..
- For Interest, as of Jun 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.09 Cr..
- For Depreciation, as of Jun 2025, the value is 0.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.40 Cr. (Mar 2025) to 0.38 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is -1.37 Cr.. The value appears to be declining and may need further review. It has decreased from 2.11 Cr. (Mar 2025) to -1.37 Cr., marking a decrease of 3.48 Cr..
- For Tax %, as of Jun 2025, the value is 0.73%. The value appears to be improving (decreasing) as expected. It has decreased from 31.75% (Mar 2025) to 0.73%, marking a decrease of 31.02%.
- For Net Profit, as of Jun 2025, the value is -1.37 Cr.. The value appears to be declining and may need further review. It has decreased from 1.44 Cr. (Mar 2025) to -1.37 Cr., marking a decrease of 2.81 Cr..
- For EPS in Rs, as of Jun 2025, the value is -5.30. The value appears to be declining and may need further review. It has decreased from 5.57 (Mar 2025) to -5.30, marking a decrease of 10.87.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 8:03 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 244 | 232 | 255 | 266 | 356 | 718 | 865 | 532 | 594 | 504 | 203 | 174 | 171 |
| Expenses | 230 | 218 | 249 | 271 | 361 | 694 | 843 | 543 | 592 | 533 | 210 | 175 | 177 |
| Operating Profit | 13 | 14 | 6 | -5 | -6 | 24 | 21 | -11 | 2 | -30 | -8 | -2 | -5 |
| OPM % | 5% | 6% | 2% | -2% | -2% | 3% | 2% | -2% | 0% | -6% | -4% | -1% | -3% |
| Other Income | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 13 | 10 | 118 | 16 | 10 | 12 |
| Interest | 8 | 10 | 13 | 11 | 5 | 6 | 14 | 15 | 14 | 14 | 0 | 0 | 0 |
| Depreciation | 3 | 4 | 3 | 3 | 6 | 6 | 15 | 17 | 16 | 16 | 2 | 1 | 2 |
| Profit before tax | 7 | 3 | -7 | -15 | -12 | 17 | -2 | -30 | -19 | 58 | 6 | 6 | 4 |
| Tax % | 27% | 28% | 8% | -9% | 2% | 37% | 95% | 3% | 7% | -1% | 22% | 24% | |
| Net Profit | 5 | 2 | -8 | -14 | -12 | 11 | -5 | -31 | -20 | 59 | 5 | 5 | 3 |
| EPS in Rs | 18.88 | 9.25 | -30.65 | -53.67 | -47.75 | 41.25 | -18.23 | -118.45 | -76.97 | 228.04 | 18.69 | 18.69 | 11.49 |
| Dividend Payout % | 18% | 22% | 0% | 0% | -2% | 5% | -16% | -3% | -4% | 1% | 16% | 67% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -60.00% | -500.00% | -75.00% | 14.29% | 191.67% | -145.45% | -520.00% | 35.48% | 395.00% | -91.53% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -440.00% | 425.00% | 89.29% | 177.38% | -337.12% | -374.55% | 555.48% | 359.52% | -486.53% | 91.53% |
Cravatex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -27% |
| 3 Years: | -34% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 25% |
| 3 Years: | 31% |
| TTM: | -39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 4% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -16% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:06 pm
Balance Sheet
Last Updated: July 25, 2025, 1:30 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 40 | 41 | 33 | 19 | 7 | 17 | -4 | -31 | -52 | 90 | 96 | 104 |
| Borrowings | 67 | 66 | 72 | 135 | 105 | 117 | 202 | 155 | 167 | 0 | 0 | 0 |
| Other Liabilities | 51 | 54 | 67 | 63 | 94 | 163 | 241 | 259 | 247 | 44 | 26 | 34 |
| Total Liabilities | 160 | 164 | 175 | 220 | 208 | 299 | 442 | 385 | 365 | 137 | 125 | 141 |
| Fixed Assets | 29 | 29 | 28 | 53 | 48 | 48 | 92 | 76 | 62 | 8 | 9 | 9 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 6 | 1 | 25 | 15 | 5 | 5 | 8 | 16 |
| Other Assets | 131 | 135 | 147 | 167 | 155 | 250 | 325 | 294 | 298 | 124 | 108 | 116 |
| Total Assets | 160 | 164 | 175 | 220 | 208 | 299 | 442 | 385 | 365 | 137 | 125 | 141 |
Below is a detailed analysis of the balance sheet data for Cravatex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
- For Reserves, as of Mar 2025, the value is 104.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Mar 2024) to 104.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.00 Cr. (Mar 2024) to 34.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 141.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2024) to 141.00 Cr., marking an increase of 16.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 8.00 Cr..
- For Other Assets, as of Mar 2025, the value is 116.00 Cr.. The value appears strong and on an upward trend. It has increased from 108.00 Cr. (Mar 2024) to 116.00 Cr., marking an increase of 8.00 Cr..
- For Total Assets, as of Mar 2025, the value is 141.00 Cr.. The value appears strong and on an upward trend. It has increased from 125.00 Cr. (Mar 2024) to 141.00 Cr., marking an increase of 16.00 Cr..
Notably, the Reserves (104.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -54.00 | -52.00 | -66.00 | -140.00 | -111.00 | -93.00 | -181.00 | -166.00 | -165.00 | -30.00 | -8.00 | -2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 113 | 115 | 106 | 84 | 106 | 76 | 72 | 98 | 82 | 19 | 25 | 50 |
| Inventory Days | 87 | 124 | 124 | 84 | 53 | 60 | 49 | 85 | 84 | 29 | 28 | 40 |
| Days Payable | 61 | 66 | 71 | 65 | 89 | 16 | 25 | 23 | 36 | 21 | 25 | 43 |
| Cash Conversion Cycle | 139 | 173 | 159 | 102 | 70 | 120 | 95 | 160 | 130 | 27 | 28 | 47 |
| Working Capital Days | 35 | 42 | 20 | -4 | 40 | 27 | 10 | 24 | 29 | 16 | 15 | 19 |
| ROCE % | 15% | 12% | 5% | -3% | -6% | 18% | 6% | -6% | -2% | -24% | 7% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| Diluted EPS (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| Cash EPS (Rs.) | 24.40 | 25.97 | 290.52 | -13.62 | -50.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 411.83 | 382.02 | 357.42 | 98.58 | 181.71 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 411.83 | 382.02 | 357.42 | 98.58 | 181.71 |
| Revenue From Operations / Share (Rs.) | 672.41 | 784.12 | 1948.99 | 2299.88 | 2058.19 |
| PBDIT / Share (Rs.) | 31.94 | 32.66 | -69.16 | 43.74 | 7.78 |
| PBIT / Share (Rs.) | 26.22 | 25.37 | -131.63 | -19.60 | -59.71 |
| PBT / Share (Rs.) | 24.66 | 23.84 | 225.73 | -71.76 | -115.13 |
| Net Profit / Share (Rs.) | 18.68 | 18.68 | 228.05 | -76.96 | -118.45 |
| NP After MI And SOA / Share (Rs.) | 18.68 | 18.68 | 228.05 | -76.95 | -118.45 |
| PBDIT Margin (%) | 4.75 | 4.16 | -3.54 | 1.90 | 0.37 |
| PBIT Margin (%) | 3.90 | 3.23 | -6.75 | -0.85 | -2.90 |
| PBT Margin (%) | 3.66 | 3.04 | 11.58 | -3.12 | -5.59 |
| Net Profit Margin (%) | 2.77 | 2.38 | 11.70 | -3.34 | -5.75 |
| NP After MI And SOA Margin (%) | 2.77 | 2.38 | 11.70 | -3.34 | -5.75 |
| Return on Networth / Equity (%) | 4.53 | 4.89 | 63.80 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 6.18 | 6.42 | -36.18 | -3.18 | -9.16 |
| Return On Assets (%) | 3.43 | 3.87 | 43.12 | -5.45 | -7.94 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | -2.14 | -2.98 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | -3.36 | -5.47 |
| Asset Turnover Ratio (%) | 1.31 | 1.55 | 0.01 | 0.01 | 0.01 |
| Current Ratio (X) | 4.22 | 5.11 | 2.95 | 1.43 | 1.39 |
| Quick Ratio (X) | 3.86 | 4.64 | 2.27 | 0.97 | 1.00 |
| Inventory Turnover Ratio (X) | 15.69 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 20.39 | 21.30 | -1.34 | 0.83 | 0.14 |
| Interest Coverage Ratio (Post Tax) (X) | 12.93 | 13.18 | -2.50 | -0.47 | -1.14 |
| Enterprise Value (Cr.) | 13.09 | 36.92 | 26.37 | 297.69 | 268.76 |
| EV / Net Operating Revenue (X) | 0.07 | 0.18 | 0.05 | 0.50 | 0.50 |
| EV / EBITDA (X) | 1.59 | 4.37 | -1.48 | 26.34 | 133.65 |
| MarketCap / Net Operating Revenue (X) | 0.50 | 0.55 | 0.16 | 0.15 | 0.14 |
| Price / BV (X) | 0.83 | 1.14 | 0.89 | -1.87 | -2.65 |
| Price / Net Operating Revenue (X) | 0.50 | 0.55 | 0.16 | 0.15 | 0.14 |
| EarningsYield | 0.05 | 0.04 | 0.71 | -0.21 | -0.40 |
After reviewing the key financial ratios for Cravatex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For Diluted EPS (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.40. This value is within the healthy range. It has decreased from 25.97 (Mar 24) to 24.40, marking a decrease of 1.57.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 411.83. It has increased from 382.02 (Mar 24) to 411.83, marking an increase of 29.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 411.83. It has increased from 382.02 (Mar 24) to 411.83, marking an increase of 29.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 672.41. It has decreased from 784.12 (Mar 24) to 672.41, marking a decrease of 111.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 31.94. This value is within the healthy range. It has decreased from 32.66 (Mar 24) to 31.94, marking a decrease of 0.72.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.22. This value is within the healthy range. It has increased from 25.37 (Mar 24) to 26.22, marking an increase of 0.85.
- For PBT / Share (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.84 (Mar 24) to 24.66, marking an increase of 0.82.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
- For PBDIT Margin (%), as of Mar 25, the value is 4.75. This value is below the healthy minimum of 10. It has increased from 4.16 (Mar 24) to 4.75, marking an increase of 0.59.
- For PBIT Margin (%), as of Mar 25, the value is 3.90. This value is below the healthy minimum of 10. It has increased from 3.23 (Mar 24) to 3.90, marking an increase of 0.67.
- For PBT Margin (%), as of Mar 25, the value is 3.66. This value is below the healthy minimum of 10. It has increased from 3.04 (Mar 24) to 3.66, marking an increase of 0.62.
- For Net Profit Margin (%), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 5. It has increased from 2.38 (Mar 24) to 2.77, marking an increase of 0.39.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 8. It has increased from 2.38 (Mar 24) to 2.77, marking an increase of 0.39.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.53. This value is below the healthy minimum of 15. It has decreased from 4.89 (Mar 24) to 4.53, marking a decrease of 0.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.18. This value is below the healthy minimum of 10. It has decreased from 6.42 (Mar 24) to 6.18, marking a decrease of 0.24.
- For Return On Assets (%), as of Mar 25, the value is 3.43. This value is below the healthy minimum of 5. It has decreased from 3.87 (Mar 24) to 3.43, marking a decrease of 0.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.31. It has decreased from 1.55 (Mar 24) to 1.31, marking a decrease of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 4.22. This value exceeds the healthy maximum of 3. It has decreased from 5.11 (Mar 24) to 4.22, marking a decrease of 0.89.
- For Quick Ratio (X), as of Mar 25, the value is 3.86. This value exceeds the healthy maximum of 2. It has decreased from 4.64 (Mar 24) to 3.86, marking a decrease of 0.78.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 15.69. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 15.69, marking an increase of 15.69.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.39. This value is within the healthy range. It has decreased from 21.30 (Mar 24) to 20.39, marking a decrease of 0.91.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 13.18 (Mar 24) to 12.93, marking a decrease of 0.25.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.09. It has decreased from 36.92 (Mar 24) to 13.09, marking a decrease of 23.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 1. It has decreased from 0.18 (Mar 24) to 0.07, marking a decrease of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 5. It has decreased from 4.37 (Mar 24) to 1.59, marking a decrease of 2.78.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.50, marking a decrease of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.14 (Mar 24) to 0.83, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.50, marking a decrease of 0.05.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cravatex Ltd:
- Net Profit Margin: 2.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.18% (Industry Average ROCE: 15.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.53% (Industry Average ROE: 9.23%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.86
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.9 (Industry average Stock P/E: 106.79)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | 1st Floor, Godrej Bhavan, 4A Home Street Mumbai Maharashtra 400001 | investors@cravatex.com http://www.cravatex.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajesh Batra | Chairman & Managing Director |
| Mr. Divakar G Kamath | Executive Director & CFO |
| Mr. Rohan Batra | Non Executive Director |
| Mr. Pheroza Jimmy Bilimoria | Independent Director |
| Mr. Satyan Shivkumar Israni | Independent Director |
| Mr. Nakul Toshniwal | Independent Director |
| Ms. Rina Suresh Deora | Independent Director |
FAQ
What is the intrinsic value of Cravatex Ltd?
Cravatex Ltd's intrinsic value (as of 27 October 2025) is 555.08 which is 38.42% higher the current market price of 401.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 104 Cr. market cap, FY2025-2026 high/low of 555/310, reserves of ₹104 Cr, and liabilities of 141 Cr.
What is the Market Cap of Cravatex Ltd?
The Market Cap of Cravatex Ltd is 104 Cr..
What is the current Stock Price of Cravatex Ltd as on 27 October 2025?
The current stock price of Cravatex Ltd as on 27 October 2025 is 401.
What is the High / Low of Cravatex Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Cravatex Ltd stocks is 555/310.
What is the Stock P/E of Cravatex Ltd?
The Stock P/E of Cravatex Ltd is 34.9.
What is the Book Value of Cravatex Ltd?
The Book Value of Cravatex Ltd is 412.
What is the Dividend Yield of Cravatex Ltd?
The Dividend Yield of Cravatex Ltd is 3.11 %.
What is the ROCE of Cravatex Ltd?
The ROCE of Cravatex Ltd is 6.57 %.
What is the ROE of Cravatex Ltd?
The ROE of Cravatex Ltd is 4.68 %.
What is the Face Value of Cravatex Ltd?
The Face Value of Cravatex Ltd is 10.0.